Schematic diagram of BENEDICT phase A type 2 diabetic patients screened for the Pro618Ala ADAMTS13. ACEi allocation: Ala carriers vs. Pro/Pro homozygotes, χ2 = 0.715, P = 0.398. Renal event development: Ala carriers, ACEi vs. non-ACEi, χ2 = 8.907, P = 0.003; Pro/Pro homozygotes, ACEi vs. non-ACEi, χ2 = 5.032, P = 0.025; ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 1.961, P = 0.161; non-ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 1.436, P = 0.231. Cardiovascular event development: Ala carriers, ACEi vs. non-ACEi, χ2 = 1.057, P = 0.304; Pro/Pro homozygotes, ACEi vs. non-ACEi, χ2 = 0.218, P = 0.641; ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 0.114, P = 0.736; non-ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 4.673, P = 0.031. Combined event development: Ala carriers, ACEi vs. non-ACEi, χ2=8.255, P = 0.004; Pro/Pro homozygotes, ACEi vs. non-ACEi, χ2 = 2.109, P = 0.146; ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 0.747, P = 0.388; non-ACEi, Ala carriers vs. Pro/Pro homozygotes, χ2 = 4.523, P = 0.033.